RayKnowChina Research Map
Shortlist0

RecruitingNasopharyngeal carcinomaPhase 3

Registered title, quoted from ClinicalTrials.gov

Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC

An open trial on nasopharyngeal carcinoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 6 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 6

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteChongqing University Cancer Hospital重庆大学附属肿瘤医院ChongqingHospital page
  2. Study siteEye & ENT Hospital of Fudan University复旦大学附属眼耳鼻喉科医院ShanghaiHospital page
  3. Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page
  4. Study siteShanghai Proton and Heavy Ion Center上海市质子重离子医院ShanghaiHospital page
  5. Study siteSichuan Cancer Hospital四川省肿瘤医院ChengduHospital page
  6. Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07303023, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 70 years; sex: all

    Registered eligibility fields

  2. Pathologically confirmed WHO type I, II, or III nasopharyngeal carcinoma.

    Inclusion criterion 2

  3. Staged as T1-4N0-3 M0, Stage I-III according to the UICC/AJCC 9th edition staging system.

    Inclusion criterion 3

  4. Hematopoietic function: Hemoglobin ≥9 g/L, Platelets ≥100×10⁹/L, WBC ≥3.5×10⁹/L, Neutrophils ≥2.0×10⁹/L.

    Inclusion criterion 7

    Liver function: ALT and AST < 2.5 × ULN, Bilirubin < 1.5 × ULN.

    Inclusion criterion 8

    Renal function: Creatinine clearance ≥50 mL/min or serum creatinine within normal range.

    Inclusion criterion 9

  5. History of immunodeficiency (positive HIV test), other acquired/congenital immunodeficiency disorders, or history of organ/allogeneic bone marrow transplantation.

    Exclusion criterion 11

  6. Pregnancy (confirmed by serum or urine β-HCG test) or lactation.

    Exclusion criterion 3

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; day-to-day activity level; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07303023, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age 18-70 years.
  • Pathologically confirmed WHO type I, II, or III nasopharyngeal carcinoma.
  • Staged as T1-4N0-3 M0, Stage I-III according to the UICC/AJCC 9th edition staging system.
  • Absence of distant metastasis confirmed by systemic FDG PET/CT (or whole-body bone scan plus chest CT and abdominal ultrasound).
  • Ability to undergo MRI examination.
  • Adequate major organ function meeting radiotherapy requirements:
  • Hematopoietic function: Hemoglobin ≥9 g/L, Platelets ≥100×10⁹/L, WBC ≥3.5×10⁹/L, Neutrophils ≥2.0×10⁹/L.
  • Liver function: ALT and AST < 2.5 × ULN, Bilirubin < 1.5 × ULN.
  • Renal function: Creatinine clearance ≥50 mL/min or serum creatinine within normal range.
  • Patients with clinical symptoms will be evaluated based on specific manifestations.
  • ECOG performance status 0-1; absence of severe comorbidities (e.g., severe pulmonary hypertension, cardiovascular disease, peripheral vascular disease, severe chronic heart disease) that may preclude radiotherapy. Cardiac function class 1-2 (NYHA classification).
  • Life expectancy ≥12 months.
  • Patients must be informed of the study details and provide written informed consent.

Exclusion Criteria:

  • Pathology not confirming WHO type I, II, or III nasopharyngeal carcinoma.
  • Distant metastasis identified clinically or radiologically before treatment, or presence of skip metastases in cervical lymph nodes.
  • Pregnancy (confirmed by serum or urine β-HCG test) or lactation.
  • Unwillingness to provide informed consent.
  • Prior radiotherapy to the head and neck region.
  • Comorbidities or other factors that may contraindicate photon or carbon-ion therapy.
  • Inability to comply with regular follow-up due to psychological, social, familial, or geographical reasons.
  • Known allergy to chemotherapeutic agents (e.g., cisplatin, docetaxel, gemcitabine) or contrast media used in the study's imaging examinations.
  • Contraindication to contrast-enhanced MRI.
  • Major organ dysfunction, or severe uncontrolled concurrent infection or medical illness (e.g., decompensated cardiac, pulmonary, renal, or hepatic failure).
  • History of immunodeficiency (positive HIV test), other acquired/congenital immunodeficiency disorders, or history of organ/allogeneic bone marrow transplantation.
  • History of other malignancies prior to enrollment (except for basal cell carcinoma of the skin).
  • History of substance or alcohol abuse.
  • Any other condition deemed by the investigator to potentially lead to study discontinuation, including co-morbidities (including psychiatric) requiring concomitant treatment, severely abnormal laboratory values, or familial/social factors compromising patient safety or data integrity.

Quoted from ClinicalTrials.gov, NCT07303023, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07303023, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07303023